Entrada Therapeutics. has been granted a patent for compounds designed to treat Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE). These compounds feature cell-penetrating peptides linked to thymidine phosphorylase, enhancing their therapeutic potential. The patent includes specific structural claims for these compounds. GlobalData’s report on Entrada Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Entrada Therapeutics, Cyclosporin derivatives was a key innovation area identified from patents. Entrada Therapeutics's grant share as of June 2024 was 17%. Grant share is based on the ratio of number of grants to total number of patents.
Compounds for treating mitochondrial neurogastrointestinal encephalopathy syndrome
The granted patent US11987821B2 describes a novel compound characterized by a specific structure defined in Formula I-A, which includes a cyclic cell-penetrating peptide (cCPP) linked to thymidine phosphorylase (TP) or its active fragments. The cCPP is required to have an amino acid sequence that is at least 95% identical to one of the specified sequences (SEQ ID NO. 1-13). The compound also features a linker (L) that connects the cCPP to the TP, with various structural options for L, including amino acids, alkylene groups, and other organic structures. The claims further detail the potential configurations of the linker and the presence of additional components, such as a water-soluble polymer like polyethylene glycol (PEG), which can enhance the compound's properties.
Additional claims elaborate on the structural variations of the compound, including specific sequences for TP and cCPP, as well as the inclusion of hydrophobic aromatic amino acids. The patent outlines that the cCPP can consist of sequences with alternating chirality and specific arrangements of amino acids, which may contribute to the compound's functionality. The claims also specify the molecular weight range for the PEG residue, emphasizing the versatility of the compound's design. Overall, the patent presents a comprehensive framework for a compound that may have significant applications in therapeutic contexts, particularly in enhancing the delivery of biologically active agents.
To know more about GlobalData’s detailed insights on Entrada Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
